NIH, Industry Launch $230M Translational Drugs, Diagnostics Push | GenomeWeb

NEW YORK (GenomeWeb News) – The National Institutes of Health said today it plans to spend nearly $230 million in a partnership with 10 pharmaceutical firms and several non-profit groups to jumpstart efforts to find targets for new drugs and diagnostics.

NIH created the Accelerating Medicines Partnership (AMP) as a new model for spurring development of drugs toward US Food and Drug Administration approval, a process which has a failure rate of 95 percent and which can take a decade and cost more than $1 billion

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.